Systemic Therapy for Lung Cancer Brain Metastases

Area of Science:

• Oncology
• Neurology
• Pharmacology

Background:

• Systemic therapy for brain metastases (BM) is evolving from chemotherapy to targeted therapies and immunotherapy.
• Targeted therapies, including tyrosine kinase inhibitors (TKIs), show efficacy against specific mutations in non-small cell lung cancer (NSCLC) brain metastases.
• Immunotherapy with checkpoint inhibitors offers an alternative for patients without targetable mutations or who do not respond to targeted agents.

Purpose of the Study:

• To review the current landscape of systemic therapies for brain metastases.
• To discuss challenges and advancements in monitoring treatment response and managing resistance.
• To explore future directions in brain metastasis management, including chemoprevention.

Main Methods:

• Review of current literature on targeted therapies and immunotherapies for brain metastases.
• Discussion of diagnostic and monitoring tools such as liquid biopsy and advanced imaging.
• Exploration of emerging strategies like chemoprevention.

Main Results:

• Targeted therapies (TKIs) demonstrate significant intracranial disease control and improved survival in NSCLC BM.
• Liquid biopsy (ctDNA, CTCs, exosomes) and radiomics are emerging tools for monitoring treatment and predicting mutational status.
• Distinguishing pseudoprogression/radionecrosis from true progression requires advanced imaging techniques, necessitating further validation.

Conclusions:

• Targeted therapies and immunotherapy represent significant progress in managing brain metastases.
• Addressing resistance and accurately monitoring treatment response are critical for optimizing patient outcomes.
• Future research should focus on novel drug development, improved monitoring techniques, and chemoprevention strategies.